1 results match your criteria: "France Center for Human Immunology[Affiliation]"
Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies.
EMBO Mol Med
June 2016
The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France INSERM U818, Paris, France Center for Human Immunology, Institut Pasteur, Paris, France Department of Cancer Immunotherapy, Genentech, South San Francisco, CA, USA
Article Synopsis
- Dipeptidyl peptidase 4 (DPP4) plays a key role in modifying the chemokine CXCL10, leading to a less effective form that hinders T-cell and NK cell movement.
- Two clinical trials were conducted to assess the effects of a DPP4 inhibitor, sitagliptin, on CXCL10 processing in both healthy individuals and chronic hepatitis C patients, who have elevated DPP4 levels.
- Results showed that sitagliptin significantly reduced the inactive form of CXCL10 while increasing the active version, demonstrating the potential of DPP4 inhibitors in therapeutic strategies for enhancing immune response.